journal
MENU ▼
Read by QxMD icon Read
search

Neuro-oncology

journal
https://www.readbyqxmd.com/read/28521052/can-telomerase-activity-be-unleashed-to-refine-prognosis-within-ependymoma-subgroups
#1
Michal Zapotocky, Vijay Ramaswamy
No abstract text is available yet for this article.
May 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28521029/soluble-taci-and-soluble-bcma-as-biomarkers-in-primary-central-nervous-system-lymphoma
#2
Franziska S Thaler, Sarah A Laurent, Marion Huber, Matthias Mulazzani, Martin Dreyling, Uwe Ködel, Tania Kümpfel, Andreas Straube, Edgar Meinl, Louisa von Baumgarten
Background: B-cell survival is regulated through interactions of B-cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). We evaluated the diagnostic potential of soluble TACI (sTACI) and soluble BCMA (sBCMA) in cerebrospinal fluid (CSF) and serum as biomarkers in primary CNS lymphoma (PCNSL). Methods: CSF (n=176) and serum samples (n=105) from patients with clinically or radiologically suspected PCNSL as well as from control patients were collected prospectively...
May 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28521009/toward-more-informative-biomarker-based-clinical-trials-in-glioblastoma
#3
Howard Colman
No abstract text is available yet for this article.
May 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28510691/nf-%C3%AE%C2%BAb-upregulation-through-epigenetic-silencing-of-ldoc1-drives-tumor-biology-and-specific-immunophenotype-in-group-a-ependymoma
#4
Andrea M Griesinger, Davis A Witt, Sydney T Grob, Sabrina R Georgio Westover, Andrew M Donson, Bridget Sanford, Jean M Mulcahy Levy, Randall Wong, Daniel C Moreira, John A DeSisto, Ilango Balakrishnan, Lindsey M Hoffman, Michael H Handler, Kenneth L Jones, Rajeev Vibhakar, Sujatha Venkataraman, Nicholas K Foreman
Background.: Inflammation has been identified as a hallmark of high-risk Group A (GpA) ependymoma (EPN). Chronic interleukin (IL)-6 secretion from GpA tumors drives an immune suppressive phenotype by polarizing infiltrating monocytes. This study determines the mechanism by which IL-6 is dysregulated in GpA EPN. Methods.: Twenty pediatric GpA and 21 pediatric Group B (GpB) EPN had gene set enrichment analysis for MSigDB Hallmark gene sets performed. Protein and RNA from patients and cell lines were used to validate transcriptomic findings...
May 16, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28499022/quantitative-imaging-biomarkers-for-risk-stratification-of-patients-with-recurrent-glioblastoma-treated-with-bevacizumab
#5
Patrick Grossmann, Vivek Narayan, Ken Chang, Rifaquat Rahman, Lauren Abrey, David A Reardon, Lawrence H Schwartz, Patrick Y Wen, Brian M Alexander, Raymond Huang, Hugo J W L Aerts
Background: Antiangiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic strategies on the basis of magnetic-resonance-imaging (MRI) have the potential to noninvasively stratify survival and progression in this patient population. Methods: In an initial cohort of 126 patients, we identified a distinct set of features representative of the radiographic phenotype on baseline (pre-treatment) MRI...
May 11, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28499018/intracystic-interferon-alpha-in-pediatric-craniopharyngioma-patients-an-international-multicenter-assessment-on-behalf-of-siope-and-ispn
#6
John-Paul Kilday, Massimo Caldarelli, Luca Massimi, Robert Hsin-Hung Chen, Yi Yen Lee, Muh-Lii Liang, Jeanette Parkes, Thuran Naiker, Marie-Lise van Veelen, Erna Michiels, Conor Mallucci, Benedetta Pettorini, Lisethe Meijer, Christian Dorfer, Thomas Czech, Manuel Diezi, Antoinette Yn Schouten-van Meeteren, Stefan Holm, Bengt Gustavsson, Martin Benesch, Hermann L Müller, Anika Hoffmann, Stefan Rutkowski, Joerg Flitsch, Gabriele Escherich, Michael Grotzer, Helen A Spoudeas, Kristian Azquikina, Michael Capra, Rolando Jiménez-Guerra, Patrick MacDonald, Donna L Johnston, Rina Dvir, Shlomi Constantini, Meng-Fai Kuo, Shih-Hung Yang, Ute Bartels
Background: Craniopharyngiomas are frequent hypothalamo-pituitary tumors in children, presenting predominantly as cystic lesions. Morbidity from conventional treatment has focused attention on intracystic drug delivery, hypothesized to cause fewer clinical consequences. However, the efficacy of intracystic therapy remains unclear. We report the retrospective experiences of several global centers using intracystic interferon-alpha. Methods: European Société Internationale d'Oncologie Pédiatrique and International Society for Pediatric Neurosurgery centers were contacted to submit a datasheet capturing pediatric patients with cystic craniopharyngiomas who had received intracystic interferon-alpha...
May 11, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28486691/combined-kinase-inhibitors-of-mek1-2-and-either-pi3k-or-pdgfr-are-efficacious-in-intracranial-triple-negative-breast-cancer
#7
Amanda E D Van Swearingen, Maria J Sambade, Marni B Siegel, Shivani Sud, Robert S McNeill, Samantha M Bevill, Xin Chen, Ryan E Bash, Louisa Mounsey, Brian T Golitz, Charlene Santos, Allison Deal, Joel S Parker, Naim Rashid, C Ryan Miller, Gary L Johnson, Carey K Anders
Background: Triple-negative breast cancer (TNBC), lacking expression of hormone and human epidermal growth factor receptor 2 receptors, is an aggressive subtype that frequently metastasizes to the brain and has no FDA-approved systemic therapies. Previous literature demonstrates mitogen-activated protein kinase kinase (MEK) pathway activation in TNBC brain metastases. Thus, we aimed to discover rational combinatorial therapies with MEK inhibition, hypothesizing that co-inhibition using clinically available brain-penetrant inhibitors would improve survival in preclinical models of TNBC brain metastases...
May 9, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28482042/bap1-mutations-in-high-grade-meningioma-implications-for-patient-care
#8
Ganesh M Shankar, Sandro Santagata
We have recently shown that the BAP1 (BRCA1-associated protein-1) tumor suppressor gene is inactivated in a subset of clinically-aggressive meningiomas that display rhabdoid histomorphology. Immunohistochemistry for BAP1 protein provides a rapid and inexpensive method for screening suspected cases. Notably, some patients with BAP1-mutant meningiomas have germline BAP1 mutations and the BAP1 tumor predisposition syndrome (BAP1-TPDS). It appears that nearly all patients with germline BAP1 mutations develop malignancies by age 55, most frequently uveal melanoma, cutaneous melanoma, pleural or peritoneal malignant mesothelioma or renal cell carcinoma, although other cancers have also been associated with the BAP1-TPDS...
May 8, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28482026/pre-clinical-drug-screen-reveals-topotecan-actinomycin-d-and-volasertib-as-potential-new-therapeutic-candidates-for-etmr-brain-tumor-patients
#9
Christin Schmidt, Nil A Schubert, Sebastian Brabetz, Norman Mack, Benjamin Schwalm, Jennifer A Chan, Florian Selt, Christel Herold-Mende, Olaf Witt, Till Milde, Stefan M Pfister, Andrey Korshunov, Marcel Kool
Background: Embryonal tumor with multilayered rosettes (ETMR) is a rare and aggressive embryonal brain tumor that solely occurs in infants and young children and has only recently been recognized as a separate brain tumor entity in the WHO classification for CNS tumors. Patients have a very dismal prognosis with a median survival of 12 months upon diagnosis despite aggressive treatment. The aim of this study was to develop novel treatment regimens in a pre-clinical drug screen in order to inform potentially more active clinical trial protocols...
May 8, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28482067/frequent-akt1e17k-mutations-in-skull-base-meningiomas-are-associated-with-mtor-and-erk1-2-activation-and-reduced-time-to-tumor-recurrence
#10
Ümmügülsüm Yesilöz, Elmar Kirches, Christian Hartmann, Johannes Scholz, Siegfried Kropf, Felix Sahm, Makoto Nakamura, Christian Mawrin
Background.: Skull base meningiomas are considered to be difficult for surgical treatment. We wondered whether genetic alterations recently identified in benign non-NF2-mutated World Health Organization (WHO) grade I meningiomas are related to clinical features of skull base meningiomas and whether druggable signaling pathways are activated. Methods.: We analyzed 93 skull base meningiomas (82 WHO grade I, 11 WHO grade II) for mutations of hot spots or the most relevant exons of AKT1, KLF4/TRAF7, SMO, PI3K, and the TERT promoter...
May 6, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28482030/global-incidence-of-malignant-brain-and-other-central-nervous-system-tumors-by-histology-2003-2007
#11
Rebecca Leece, Jordan Xu, Quinn T Ostrom, Yanwen Chen, Carol Kruchko, Jill S Barnholtz-Sloan
Background: Previous reports have shown that overall incidence of malignant brain and other central nervous system (CNS) tumors varied significantly by country. The aim of this study was to estimate histology-specific incidence rates by global region and assess incidence variation by histology and age. Methods: Using data from the Central Brain Tumor Registry of the United States and the International Agency for Research on Cancer's Cancer Incidence in Five Continents X (including over 300 cancer registries), we calculated the age-adjusted incidence rates (AAIR) per 100,000 person-years and 95% confidence intervals (95% CI) for brain and other CNS tumors overall, and by age groups and histology...
May 6, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28475775/autocrine-activation-of-the-ifn-signaling-pathway-may-promote-immune-escape-in-glioblastoma
#12
Manuela Silginer, Sara Nagy, Caroline Happold, Hannah Schneider, Michael Weller, Patrick Roth
Background.: Interferons (IFNs) are cytokines typically induced upon viral infection but are constitutively expressed also in the absence of acute infection. The physiological role of autocrine and paracrine IFN signaling, however, remains poorly understood, and its function in glioblastoma has not been explored in depth. Methods.: Using RNA interference-mediated gene silencing, we characterized constitutive type I IFN signaling and its role in human glioma cells...
May 5, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28472527/biopsy-of-enlarging-lesions-after-stereotactic-radiosurgery-for-brain-metastases-frequently-reveals-radiation-necrosis
#13
Jessica L Narloch, S Harrison Farber, Sarah Sammons, Frances McSherry, James E Herndon, Jenny K Hoang, Fang-Fang Yin, John H Sampson, Peter E Fecci, Kimberly L Blackwell, John P Kirkpatrick, Grace J Kim
Background: Stereotactic radiosurgery (SRS) offers excellent local control for brain metastases (BM) with low rates of toxicity. Radiation necrosis (RN) may occur after treatment and is challenging to distinguish from local recurrence (LR). We evaluated enlarging brain lesions following SRS that were subsequently biopsied to differentiate RN versus LR. Methods: This study reviewed patients receiving SRS for BM between 2008-2012 who underwent a biopsy for suspicion of RN versus LR on MRI imaging...
May 3, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28472509/multicenter-phase-ii-study-of-temozolomide-and-myeloablative-chemotherapy-with-autologous-stem-cell-transplant-for-newly-diagnosed-anaplastic-oligodendroglioma
#14
Alissa A Thomas, Lauren E Abrey, Robert Terziev, Jeffrey Raizer, Nina L Martinez, Peter Forsyth, Nina Paleologos, Matthew Matasar, Craig S Sauter, Craig Moskowitz, Stephen D Nimer, Lisa M DeAngelis, Thomas Kaley, Sean Grimm, David N Louis, J Gregory Cairncross, Katherine S Panageas, Samuel Briggs, Geraldine Faivre, Nimish A Mohile, Jayesh Mehta, Philip Jonsson, Debyani Chakravarty, Jianjiong Gao, Nikolaus Schultz, Cameron W Brennan, Jason T Huse, Antonio Omuro
Background: Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytomas (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT), as a potential strategy to defer radiotherapy. Methods: Patients with AO/AOA received 6 cycles of TMZ (200mg/m2 X5/28-day). Responding patients were eligible for HDC (thiotepa 250mg/m2/day X3 days then busulfan 3...
May 2, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28453784/detection-of-wtegfr-amplification-and-egfrviii-mutation-in-csf-derived-extracellular-vesicles-of-glioblastoma-patients
#15
Javier M Figueroa, Johan Skog, Johnny Akers, Hongying Li, Ricardo Komotar, Randy Jensen, Florian Ringel, Isaac Yang, Steven Kalkanis, Reid Thompson, Lori LoGuidice, Emily Berghoff, Andrew Parsa, Linda Liau, William Curry, Daniel Cahill, Chetan Bettegowda, Frederick F Lang, E Antonio Chiocca, John Henson, Ryan Kim, Xandra Breakefield, Clark Chen, Karen Messer, Fred Hochberg, Bob S Carter
Background: RNA within extracellular vesicles (EVs) have potential as diagnostic biomarkers for patients with cancer, and are identified in a variety of biofluids. Glioblastomas (GBMs) release EVs containing RNA into cerebrospinal fluid (CSF). Here we describe a multi-institutional study of RNA extracted from CSF-derived EVs of GBM patients, for the presence of tumor-associated amplifications and mutations in the epidermal growth factor receptor (EGFR). Methods: CSF and matching tumor tissue were obtained from patients undergoing resection of GBMs...
April 27, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28449033/response-assessment-in-medulloblastoma-and-leptomeningeal-seeding-tumors-recommendations-from-the-response-assessment-in-pediatric-neuro-oncology-committee
#16
Katherine E Warren, Gilbert Vezina, Tina Y Poussaint, Monika Warmuth-Metz, Marc C Chamberlain, Roger J Packer, Alba A Brandes, Moshe Reiss, Stewart Goldman, Michael J Fisher, Ian F Pollack, Michael D Prados, Patrick Y Wen, Susan M Chang, Christelle Dufour, David Zurakowski, Rolf D Kortmann, Mark W Kieran
Lack of standard response criteria in clinical trials for medulloblastoma and other seeding tumors complicates assessment of therapeutic efficacy and comparisons across studies. An international working group was established to develop consensus recommendations for response assessment. The aim is that these recommendations be prospectively evaluated in clinical trials, with the goal of achieving more reliable risk stratification and uniformity across clinical trials. Current practices and literature review were performed to identify major confounding issues and justify subsequently developed recommendations; in areas lacking scientific investigations, recommendations were based on experience of committee members and consensus was reached after discussion...
April 25, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28444227/incidence-and-prognosis-of-patients-with-brain-metastases-at-diagnosis-of-systemic-malignancy-a-population-based-study
#17
Daniel N Cagney, Allison M Martin, Paul J Catalano, Amanda J Redig, Nancy U Lin, Eudocia Q Lee, Patrick Y Wen, Ian F Dunn, Wenya Linda Bi, Stephanie E Weiss, Daphne A Haas-Kogan, Brian M Alexander, Ayal A Aizer
Background: Brain metastases are associated with significant morbidity and mortality. Population-level data describing the incidence and prognosis of patients with brain metastases are lacking. The aim of this study was to characterize the incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy using recently released data from the Surveillance, Epidemiology, and End Results (SEER) program. Methods: We identified 1,302,166 patients diagnosed with non-hematologic malignancies originating outside of the central nervous system between 2010-2013 and described the incidence proportion and survival of patients with brain metastases...
April 24, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28444219/dna-methylation-of-a-novel-pak4-locus-influences-ototoxicity-susceptibility-following-cisplatin-and-radiation-therapy-for-pediatric-embryonal-tumors
#18
Austin L Brown, Kayla L Foster, Philip J Lupo, Erin C Peckham-Gregory, Jeffrey C Murray, M Fatih Okcu, Ching C Lau, Surya P Rednam, Murali Chintagumpala, Michael E Scheurer
Background: Ototoxicity is a common adverse side effect of platinum chemotherapy and cranial radiation therapy; however, individual susceptibility is highly variable. Therefore, the objective of this study was to conduct an epigenome-wide association study to identify differentially methylated CpG sites associated with ototoxicity susceptibility among cisplatin-treated pediatric patients with embryonal tumors. Methods: Samples were collected for a discovery (n=62) and a replication cohort (n=18) of medulloblastoma and primitive neuroectodermal tumor patients...
April 24, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28419308/brain-invasion-in-meningiomas-clinical-considerations-and-impact-of-neuropathological-evaluation-a-systematic-review
#19
Benjamin Brokinkel, Katharina Hess, Christian Mawrin
With the release of the 2016 edition of the WHO Classification of Central Nervous System tumors, brain invasion in meningiomas has been added as a stand-alone criterion for atypia and can therefore impact grading and indirectly adjuvant therapy. Regarding this rising clinical importance, we have reviewed the current knowledge about brain invasion with emphasis on its implications on current and future clinical practice. We found various definitions of brain invasion and approaches for evaluation in surgically obtained specimen described over the past decades...
April 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28419303/tumor-microtubes-convey-resistance-to-surgical-lesions-and-chemotherapy-in-gliomas
#20
Sophie Weil, Matthias Osswald, Gergely Solecki, Julia Grosch, Erik Jung, Dieter Lemke, Miriam Ratliff, Daniel Hänggi, Wolfgang Wick, Frank Winkler
Background: Primary and adaptive resistance against chemo- and radiotherapy, and local recurrence after surgery limit the benefits from these standard treatments in glioma patients. Recently we found that glioma cells can extend ultra-long membrane protrusions, "tumor microtubes" (TMs), for brain invasion, proliferation, and interconnection of single cells to a syncytium that is resistant to radiotherapy. We wondered whether TMs also convey resistance to the other two standard treatment modalities...
April 17, 2017: Neuro-oncology
journal
journal
34661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"